Cover Image
市場調查報告書

人類乳突病毒·巨細胞病毒治療藥的全球市場 (各類型藥物·各用途) :產業分析,開發平台分析,市場規模·佔有率·成長率·趨勢·未來預測

Human Papillomavirus (By Drug Class and Applications) and Cytomegalovirus (By Drug Type and Applications) Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

出版商 Transparency Market Research 商品編碼 324612
出版日期 內容資訊 英文 117 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
人類乳突病毒·巨細胞病毒治療藥的全球市場 (各類型藥物·各用途) :產業分析,開發平台分析,市場規模·佔有率·成長率·趨勢·未來預測 Human Papillomavirus (By Drug Class and Applications) and Cytomegalovirus (By Drug Type and Applications) Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
出版日期: 2015年01月14日 內容資訊: 英文 117 Pages
簡介

本報告提供全球的人類乳突病毒 (HPV) 及巨細胞病毒 (CMV) 治療藥的市場·產業相關分析,提供您疾病概要和到目前為止的臨床實驗的進展,基本的產業結構·競爭力,主要的開發中產品,成長促進·阻礙因素,藥物的各類型·各用途·地區別的市場趨勢預測(過去4年·今後5年份),以及主要企業簡介等調查評估。

第1章 簡介

第2章 摘要整理

第3章 全球HPV及CMV治療市場概要

  • 市場定義及概要
  • 市場動態
    • 人類乳突病毒 (HPV) 治療藥市場
      • 推動因素
      • 阻礙因素
      • 市場機會
    • 巨細胞病毒 (CMV) 治療藥市場
      • 推動因素
      • 阻礙因素
      • 市場機會
  • 價值鏈分析
  • 人類乳突病毒(HPV)疫苗:目前全球市場方案
  • HPV的藥物治療體制分析:HPV的藥物治療期間 (日數)
  • HPV外科治療:手術的種類及平均成本
  • 價格分析
    • 價格分析:HPV治療藥市場
    • 價格分析:CMV治療市場
    • HPV治療成本分析
    • CMV治療成本分析
  • 波特的五力分析
  • 市場魅力分析:各地區
  • 主要企業的市場佔有率分析(%)

第4章 全球HPV治療藥市場

  • 概要
  • HPV治療藥市場:各類藥物
    • 概要
    • 免疫調節物質
    • 角質溶解藥
    • 抗癌藥物
    • Sinecatechins
  • HPV治療藥市場:各用途的明細
    • 概要
    • 生殖器濕疣
    • 性器官癌症
    • 疣狀表皮發育不良
    • 口服乳頭腫
    • 其他 (口咽癌, 喉乳頭腫等)
  • HPV治療藥市場:開發平台分析
    • HPV治療藥:初期階段 (第一階段·第二階段) 的藥物候補
    • HPV治療藥:後期階段 (第三階段) 的藥物候補

第5章 全球CMV治療藥市場

  • 簡介
    • 全球CMV治療藥的市場收益額
  • CMV治療市場:主要的抗病毒藥物的情況
    • 概要
    • Ganciclovir/Valganciclovir
    • Foscarnet
    • Cidofovir
  • CMV治療藥市場:各用途
    • 概要
    • CMV視網膜炎
    • 肺炎
    • 消化管潰瘍
    • 腦炎
    • 其他 (口腔潰瘍, 咽頭炎)
  • CMV治療藥市場:開發平台分析
    • CMV治療藥:初期階段 (第一階段·第二階段) 的藥物候補
    • CMV治療藥:後期階段 (第三階段) 的藥物候補
      • 簡介
        • MK8228/letermovir/AIC246
        • Brincidofovir/CMX001

第6章 全球HPV·CMV治療藥市場:各地區的明細

  • 概要
  • 北美
    • 北美的HPV治療藥市場
    • 北美的CMV治療藥市場
  • 歐洲
  • 亞太地區
  • 南美
  • 其他地區 (ROW)

第7章 建議

  • 由於幾乎所有第一選擇藥專利都將到期,新分子用於市場上的各個領域
  • 在非洲建立強力的市場

第8章 企業簡介

  • AbbVie Inc.
    • 企業概要
    • 財務概要
    • 產品系列
    • 產業策略
    • 企業合併·收購 (M&A)
    • 最近的發展趨勢
  • Actavis plc
  • Clinigen Group plc
  • Merck & Co., Inc.
  • Perrigo Company plc
  • Roche Holdings AG
  • Valeant Pharmaceuticals International, Inc.

圖表一覽

目錄

Human papillomavirus (HPV) and Cytomegalovirus (CMV) therapeutics market report studies current as well as future prospects of the market on a global scale. The global market for HPV therapeutics is segmented by drug class and applications. Various drug classes applied against HPV infections are immunomodulators, keratolytic agents, anti-neoplastic agents, and sinecatechins. The HPV therapeutics market is studied by application segments which include genital warts, genital cancers, epidermodysplasia verriformis, oral papillomas, and others (oropharyngeal cancer, laryngeal papillomatosis and others). The global HPV therapeutics market has been extensively analyzed on the basis of the effectiveness and sales revenue of major drug classes as well as geographic prevalence of various HPV infections.

The global CMV therapeutics market is segmented by drugs and applications. The major drugs prescribed for the treatment of CMV infections are ganciclovir, valganciclovir, foscarnet, and cidofovir. The CMV therapeutics treatment is applied against various CMV infections causing retinitis, pneumonia, gastrointestinal ulcers, encephalitis and others (mouth ulcers, pharyngitis and others).

Geographically, the HPV and CMV therapeutics market has been categorized into five regions namely, North America, Europe, South America, Asia Pacific, and Rest of the World (ROW). The market size and forecast in terms of USD million for each of these segments has been provided for the period 2012 to 2020, considering 2012 and 2013 as base years. The HPV and CMV therapeutics market report also provides compounded annual growth rate (CAGR %) for each market segment for the forecast period 2014 to 2020.

The report also provides pipeline analysis for HPV and CMV therapeutics market, which includes sales forecast for drug candidates currently under phase III clinical trials, and also mentions other candidates in phase I and phase II trials. The research study explains the competitive scenario in the HPV and CMV therapeutics market through Porter's Five Forces Analysis. A detailed analysis of various macro as well as micro economic factors driving as well as restraining the growth of this market, in addition to future opportunities, is provided in the market overview section of the report. The report also provides market attractiveness analysis and value chain analysis of the global HPV and CMV therapeutics market. Market share analysis for both HPV and CMV therapeutics market has been included. Furthermore, pricing analysis of therapeutic drugs and costs associated with treatment is also studied in the global HPV and CMV therapeutics market report.

A list of recommendations has been provided to help players establish a strong presence in the market and increase their share. The report also profiles major players in the HPV and CMV therapeutics market on the basis of various attributes such as company overview, financial overview, product portfolio, business strategies and recent developments. Mergers, acquisitions, regulatory approvals and other events have been explained in the company profiles section. Key players profiled in the report include AbbVie, Inc., Actavis plc, Clinigen Group plc, Merck & Co., Inc., Perrigo Company plc, Roche Holdings AG and Valeant Pharmaceuticals International, Inc.

The research methodology was based on primary as well as secondary research. Interviews and discussions with a wide range of key industry participants and opinion leaders revealed the real time market scenario. This primary research represented the bulk of our research efforts, which was further supplemented by extensive secondary research. A bottom-up approach was adopted to arrive at global market shares for 2012 and 2013; while an impact based analysis model was adopted to forecast revenue for each market segment. A review of key players' product literature, annual reports, and press releases supported the market forecast analysis. The 117 pages global HPV and CMV therapeutics market report describes various market dynamics in 51 figures and charts and 16 tables.

Table of Contents

Chapter 1 - Introduction

  • 1.1. Report Description
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Assumptions
  • 1.5. List of Abbreviations

Chapter 2 - Executive Summary

  • 2.1. Market Snapshot: Global HPV Therapeutics Market
  • 2.2. Market Snapshot: Global CMV Therapeutics Market
  • 2.3. Global HPV and CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

Chapter 3 - Global HPV and CMV Therapeutics Market Overview

  • 3.1. Market Definition and Overview
  • 3.2. Market Dynamics
    • 3.2.1. Human Papillomavirus (HPV) Therapeutics Market
      • 3.2.1.1. Drivers
        • 3.2.1.1.1. Increasing prevalence of HPV infections in developing and underdeveloped economies is aiding the market growth
        • 3.2.1.1.2. Global Age-specific incidence of cervical cancer
        • 3.2.1.1.3. Severe side-effects of HPV vaccines are restraining the market growth and creating opportunity for therapeutics market
      • 3.2.1.2. Restraints
        • 3.2.1.2.1. Increasing demand for minimally invasive surgical procedures in genital warts treatment
        • 3.2.1.2.2. Lack of awareness in developing areas is declining the diagnostic rates
          • 3.2.1.2.2.1. Annual number of new cases (in thousands) of cervical cancer by age group in developed and developing regions (estimations for 2012)
      • 3.2.1.3. Opportunities
        • 3.2.1.3.1. Opportunity for biologics and drugs with low toxicity and short treatment regime against HPV infections
        • 3.2.1.3.2. Health issues raised against approved vaccines have provided wide range of opportunities for effective and safe vaccines and therapeutics
    • 3.2.2. Cytomegalovirus Therapeutics Market
      • 3.2.2.1. Drivers
        • 3.2.2.1.1. High seroprevalence adding to patient pool for CMV therapeutics market
        • 3.2.2.1.2. High global demand for low-cost generic drugs, especially in low- and middle-income countries in South Latin America and Asia Pacific
      • 3.2.2.2. Restraints
        • 3.2.2.2.1. Decreasing CMV prevalence due to highly actively antiretroviral therapy (HAART) and decreasing transplant procedures
      • 3.2.2.3. Opportunities
        • 3.2.2.3.1. Less competition in pediatric CMV therapeutics and increasing demand for CMV vaccine
  • 3.3. Value Chain Analysis
  • 3.4. HPV Vaccines : Current Global Scenario
  • 3.5. HPV Drug Treatment Regime Analysis: Length of HPV Drug treatment (No. of days)
  • 3.6. HPV Surgery Treatment: Type of Surgery and Average Cost (USD)
  • 3.7. Pricing Analysis
    • 3.7.1. Pricing Analysis: HPV Therapeutics Market
    • 3.7.2. Pricing Analysis: CMV Therapeutics Market
    • 3.7.3. HPV Treatment Cost Analysis
    • 3.7.4. CMV Treatment Cost Analysis
  • 3.8. Porter's Five Forces Analysis: Global HPV & CMV Therapeutics Market
    • 3.8.1. Bargaining Power of Suppliers
    • 3.8.2. Bargaining Power of Buyers
    • 3.8.3. Threat of Substitutes
    • 3.8.4. Threat of New Entrants
    • 3.8.5. Competitive Rivalry
  • 3.9. Market Attractiveness Analysis, by Geography, 2013
    • 3.9.1. HPV Therapeutics Market Attractiveness Analysis, Geography, 2013
    • 3.9.2. CMV Therapeutics Market Attractiveness Analysis, by Geography, 2013
  • 3.10. Market Share Analysis, by Key Players, 2013 (Value %)
    • 3.10.1. HPV Therapeutics Market Share Analysis, by Key Players, 2013 (Value %)
    • 3.10.2. CMV Therapeutics Market Share Analysis, by Key Players, 2013 (Value %)

Chapter 4 - Global HPV Therapeutics Market

  • 4.1. Overview
  • 4.2. HPV Therapeutics Market, by Drug Class
    • 4.2.1. Overview
      • 4.2.1.1. Global HPV Therapeutics Market Revenue, by Major Drug Classes, 2012 - 2020 (USD Million)
    • 4.2.2. Immunomodulators
      • 4.2.2.1. Global Immunomodulators Market Revenue, 2012 - 2020 (USD Million)
    • 4.2.3. Keratolytic Agents
      • 4.2.3.1. Global Keratolytic Agents Market Revenue, 2012 - 2020 (USD Million)
    • 4.2.4. Anti-neoplastic Agents
      • 4.2.4.1. Global Anti-neoplastic Agents Market Revenue, 2012 - 2020 (USD Million)
    • 4.2.5. Sinecatechins
      • 4.2.5.1. Global Sinecatechins Market Revenue, 2012 - 2020 (USD Million)
  • 4.3. HPV Therapeutics Market, by Application
    • 4.3.1. Overview
      • 4.3.1.1. Global HPV Therapeutics Market Revenue, by Applications, 2012 - 2020 (USD Million)
    • 4.3.2. Genital Warts
      • 4.3.2.1. Global Genital Warts HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 4.3.3. Genital Cancer
      • 4.3.3.1. Global Genital Cancer HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 4.3.4. Epidermodysplasia Verruciformis
      • 4.3.4.1. Global Epidermodysplasia Verruciformis HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 4.3.5. Oral Papillomas
      • 4.3.5.1. Global Oral Papillomas HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 4.3.6. Others (Oropharyngeal cancer, laryngeal papillomatosis and others)
      • 4.3.6.1. Global Other (Oropharyngeal Cancer, Laryngeal Papillomatosis and Others) HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 4.4. HPV Therapeutics Market, Pipeline Analysis
    • 4.4.1. HPV Therapeutics: Early Stage (Phase I and Phase II) Drug Candidates
    • 4.4.2. HPV Therapeutics: Late Stage (Phase III) Drug Candidates

Chapter 5 - Global Cytomegalovirus Therapeutics Market

  • 5.1. Introduction
    • 5.1.1. Global CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 5.2. CMV Therapeutics Market, by Major Antiviral Drugs
    • 5.2.1. Overview
      • 5.2.1.1. Global CMV Therapeutics Market Revenue, by Drugs, 2012 - 2020 (USD Million)
    • 5.2.2. Ganciclovir/Valganciclovir
      • 5.2.2.1. Global Ganciclovir/Valganciclovir Market Revenue, 2012 - 2020 (USD Million)
    • 5.2.3. Foscarnet
      • 5.2.3.1. Global Foscarnet Market Revenue, 2012 - 2020 (USD Million)
    • 5.2.4. Cidofovir
      • 5.2.4.1. Global Cidofovir Market Revenue, 2012 - 2020 (USD Million)
  • 5.3. CMV Therapeutics Market, by Applications
    • 5.3.1. Overview
      • 5.3.1.1. Global CMV Therapeutics Market Revenue, by Applications, 2012 - 2020 (USD Million)
    • 5.3.2. CMV Retinitis
      • 5.3.2.1. Global CMV Retinitis Therapeutics Market Revenue,2012 - 2020 (USD Million)
    • 5.3.3. Pneumonia
      • 5.3.3.1. Global CMV Pneumonia Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 5.3.4. Gastrointestinal ulcers
      • 5.3.4.1. Global CMV Gastrointestinal Ulcers Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 5.3.5. Encephalitis
      • 5.3.5.1. Global CMV Encephalitis Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 5.3.6. Others (Mouth ulcers, pharyngitis)
      • 5.3.6.1. Global Other (Mouth ulcers, Pharyngitis)CMV Therapeutics Market Revenue,2012 - 2020 (USD Million)
  • 5.4. CMV Therapeutics Market, Pipeline Analysis
    • 5.4.1. CMV Therapeutics: Early Stage (Phase I and Phase II) Drug Candidates
    • 5.4.2. CMV Therapeutics: Late Stage (Phase III) Drug Candidates
      • 5.4.2.1. Introduction
        • 5.4.2.1.1. MK8228/ letermovir/AIC246
          • 5.4.2.1.1.1. Global Letermovir Market Revenue, 2018 - 2020 (USD Million)
        • 5.4.2.1.2. Brincidofovir/CMX001
          • 5.4.2.1.2.1. Global Brincidofovir Market Revenue, 2016 - 2020 (USD Million)

Chapter 6 - Global HPV and CMV Therapeutics Market, by Geography

  • 6.1. Overview
    • 6.1.1. Global HPV Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
      • 6.1.1.1. Global CMV Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
  • 6.2. North America
    • 6.2.1. North America HPV Therapeutics Market
      • 6.2.1.1. North America HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 6.2.2. North America CMV Therapeutics Market
      • 6.2.2.1. North America CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe HPV Therapeutics Market
      • 6.3.1.1. Europe HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 6.3.2. Europe CMV Therapeutics Market
      • 6.3.2.1. Europe CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific HPV Therapeutics Market
      • 6.4.1.1. Asia Pacific HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 6.4.2. Asia Pacific CMV Therapeutics Market
      • 6.4.2.1. Asia Pacific CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 6.5. South America
    • 6.5.1. South America HPV Therapeutics Market
      • 6.5.1.1. South America HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 6.5.2. South America CMV Therapeutics Market
      • 6.5.2.1. South America CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 6.6. Rest of the World
    • 6.6.1. Rest of the World HPV Therapeutics Market
      • 6.6.1.1. Rest of the World HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 6.6.2. Rest of the World CMV Therapeutics Market
      • 6.6.2.1. Rest of the World CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

Chapter 7 - Recommendations

  • 7.1.1. Market avails wide scope for new molecules as most of the first line drugs have been off patented
  • 7.1.2. Building stronger market hold in Africa

Chapter 8 - Company Profiles

  • 8.1. AbbVie, Inc.
    • 8.1.1. Company Overview
    • 8.1.2. Financial Overview
    • 8.1.3. Product Portfolio
    • 8.1.4. Business Strategies
      • 8.1.4.1. Strategic Collaborations and Agreements
    • 8.1.5. Mergers and Acquisitions
    • 8.1.6. Recent Developments
  • 8.2. Actavis plc
    • 8.2.1. Company Overview
    • 8.2.2. Financial Overview
    • 8.2.3. Product Portfolio
    • 8.2.4. Business Strategies
      • 8.2.4.1. Mergers and acquisitions
      • 8.2.4.2. Extensive R&D practices
      • 8.2.4.3. Strategic collaborations
    • 8.2.5. Recent Developments
  • 8.3. Clinigen Group plc
    • 8.3.1. Company Overview
    • 8.3.2. Financial Overview
    • 8.3.3. Product Portfolio
    • 8.3.4. Business Strategies
      • 8.3.4.1. Mergers and Acquisitions
    • 8.3.5. Recent Developments
  • 8.4. Merck & Co., Inc.
    • 8.4.1. Company Overview
    • 8.4.2. Financial Overview
    • 8.4.3. Product Portfolio
    • 8.4.4. Business Strategies
      • 8.4.4.1. Mergers and acquisitions
      • 8.4.4.2. Strategic collaborations
      • 8.4.4.3. Expansion in emerging markets
    • 8.4.5. Recent Developments
  • 8.5. Perrigo Company plc
    • 8.5.1. Company Overview
    • 8.5.2. Financial Overview
    • 8.5.3. Product Portfolio
    • 8.5.4. Business Strategies
    • 8.5.5. Mergers and Acquisitions
    • 8.5.6. Recent Developments
  • 8.6. Roche Holdings AG
    • 8.6.1. Company Overview
    • 8.6.2. Financial Overview
    • 8.6.3. Product Portfolio
    • 8.6.4. Business Strategies
      • 8.6.4.1. Consistent product launches
      • 8.6.4.2. Mergers and Acquisitions
    • 8.6.5. Recent Developments
  • 8.7. Valeant Pharmaceuticals International, Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Financial Overview
    • 8.7.3. Product Portfolio
    • 8.7.4. Business Strategies
      • 8.7.4.1. Mergers and acquisitions
    • 8.7.5. Recent Developments

List of Figures

  • FIG. 1: HPV Therapeutics: Market Segmentation
  • FIG. 2: CMV Therapeutics: Market Segmentation
  • FIG. 3: Global HPV and CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 4: Global Age-specific incidence of cervical cancer
  • FIG. 5: Annual number of new cases (in thousands) of cervical cancer by age group in developed and developing regions and five continents (estimations for 2012)
  • FIG. 6: Heat Map Analysis: Immunization Array of Currently Marketed Vaccines by Major Countries
  • FIG. 7: Global Human Immunodeficiency Virus (HIV) Prevalence, 1990 - 2008
  • FIG. 8: U.S. Transplant Procedures, 2000 - 2013
  • FIG. 9: Global HPV and CMV Therapeutics Market, Value Chain Analysis
  • FIG. 10: Porter's Five Forces Analysis for the Global HPV & CMV Therapeutics Market
  • FIG. 11: HPV Therapeutics Market Attractiveness Analysis: by Geography, 2013
  • FIG. 12: CMV Therapeutics Market Attractiveness Analysis, by Geography, 2013
  • FIG. 13: HPV Therapeutics Market Share Analysis: by Key Players, 2013 (Value %)
  • FIG. 14: CMV Therapeutics Market Attractiveness Analysis: by Key Players, 2013 (Value %)
  • FIG. 15: Global Immunomodulators Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 16: Global Keratolytic Agents Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 17: Global Anti-neoplastic Agents Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 18: Global Sinecatechins Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 19: Global Genital Warts HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 20: Global Genital Cancer HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 21: Global Epidermodysplasia Verruciformis HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 22: Global Oral Papillomas HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 23: Global Other (Oropharyngeal Cancer, Laryngeal Papillomatosis and Others) HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 24: Global Ganciclovir/Valganciclovir Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 25: Global Foscarnet Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 26: Global Cidofovir Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 27: Global CMV Retinitis Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 28: Global CMV Pneumonia Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 29: Global CMV Gastrointestinal Ulcers Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 30: Global CMV Encephalitis Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 31: Global Other (Mouth ulcers, Pharyngitis) CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 32: Global Letermovir Market Revenue, 2018 - 2020 (USD Million)
  • FIG. 33: Global Brincidofovir Market Revenue, 2016 - 2020 (USD Million)
  • FIG. 34: North America HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 35: North America CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 36: Europe HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 37: Europe CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 38: Asia Pacific HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 39: Asia Pacific CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 40: South America HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 41: South America CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 42: Rest of the World HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 43: Rest of the World CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 44: Tuberculosis Cases in Africa, 1996 - 2010 (‘000)
  • FIG. 45: AbbVie, Inc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 46: Actavis Inc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 47: Clinigen Group plc: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 48: Merck & Co., Inc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 49: Perrigo Company plc: Annual Revenue: 2011 - 2013 (USD Million)
  • FIG. 50: Roche Holdings AG: Annual Revenue: 2011 - 2013 (USD Million)
  • FIG. 51: Valeant Pharmaceuticals International, Inc.: Annual Revenue, 2011 - 2013 (USD Million)

List of Tables

  • TABLE 1: Market Snapshot: Global HPV Therapeutics Market
  • TABLE 2: Market Snapshot: Global CMV Therapeutics Market
  • TABLE 3: HPV Vaccines Sales Track
  • TABLE 4: Pricing Analysis: HPV Therapeutics Market
  • TABLE 5: Pricing Analysis: CMV Therapeutics Market
  • TABLE 6: HPV Strains and Diseases
  • TABLE 7: Global HPV Therapeutics Market Revenue, by Major Drug Classes, 2012 - 2020 (USD Million)
  • TABLE 8: Global HPV Therapeutics Market Revenue, by Applications, 2012 - 2020 (USD Million)
  • TABLE 9: HPV Therapeutics: Early Stage (Phase I and Phase II) Drug Candidates
  • TABLE 10: Global CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • TABLE 11: Global CMV Therapeutics Market Revenue, by Drugs, 2012 - 2020 (USD Million)
  • TABLE 12: Global CMV Therapeutics Market Revenue, by Applications, 2012 - 2020 (USD Million)
  • TABLE 13: CMV Therapeutics: Early Stage (Phase I and Phase II) Drug Candidates
  • TABLE 14: Global HPV Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
  • TABLE 15: Global CMV Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
Back to Top